This federal contract award is for a delivery order to RLS (USA) Inc., a foreign-owned, for-profit radiopharmacy company, for the provision of radiopharmaceuticals such as gallium-67, fluorodeoxyglucose F-18, thallium-201, technetium-99m, and gallium-68 dotatate. The contract, valued at $378,281.55, is a firm fixed price delivery order with a period of performance through March 31, 2026.
RLS (USA) Inc. is the prime contractor and operates 31 radiopharmacy facilities across 18 states to support nuclear medicine diagnostic services at Department of Veterans Affairs (VA) medical centers and military treatment facilities. The contract is awarded by the VA, specifically VA VISN 21, to supply critical radiopharmaceuticals used in nuclear imaging procedures for veterans and military personnel. This contract is not designated as a small business set-aside.
RLS (USA) Inc. holds several Indefinite Delivery Vehicles (IDVs) with the VA and Defense Health Agency (DHA) for the procurement of radiopharmaceuticals, including a $4,998,603.38 contract with VA VISN 17 and a $1,914,116.40 contract with the DHA.
Generated 1/1/25, 9:07 AM